Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib

Xu Jiasheng; Jiang Qidi; Xu Hua; Liu Anwen; Huang Long

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib

【24h】

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib

机译：具有NSCLC的两名患者，其EGFR基因中具有新型重复突变（P.I740_K745dupipvaik）及其对Osimertinib的反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2020年第4期|共3页
作者
Xu Jiasheng; Jiang Qidi; Xu Hua; Liu Anwen; Huang Long;
展开▼
作者单位

Nanchang Univ Dept Oncol Affiliated Hosp 2 Jiangxi Key Lab Clin &

Translat Canc Res 1 Minde Rd;

Nanchang Univ Dept Oncol Affiliated Hosp 2 Jiangxi Key Lab Clin &

Translat Canc Res 1 Minde Rd;

Nanchang Univ Dept Oncol Affiliated Hosp 2 Jiangxi Key Lab Clin &

Translat Canc Res 1 Minde Rd;

Nanchang Univ Dept Oncol Affiliated Hosp 2 Jiangxi Key Lab Clin &

Translat Canc Res 1 Minde Rd;

Nanchang Univ Dept Oncol Affiliated Hosp 2 Jiangxi Key Lab Clin &

Translat Canc Res 1 Minde Rd;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib [J] . Xu Jiasheng, Jiang Qidi, Xu Hua, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2020,第4期

机译：具有NSCLC的两名患者，其EGFR基因中具有新型重复突变（P.I740_K745dupipvaik）及其对Osimertinib的反应
2. The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations [J] . Puyu Shi, Shuo Zhang, Lei Zhu, Translational Oncology . 2019,第5期

机译：第三代EGFR抑制剂Osimertinib促进c-FLIP降解，增强包括TRAIL诱导的激活EGFR突变在内的NSCLC细胞的凋亡。
3. Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation [J] . Zhou Fei, Zhao Wencheng, Chen Xiaoxia, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2020,第1期

机译：响应Dabrafenib，Trametinib和Osimertinib在患有收购BRAF（V600E）突变的患者中的患者中的患者
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. Mutation profiling in colorectal cancer patients with microsatellite instability; High frequency of BRCA2 and EGFR somatic mutations [D] . Deihimi, Safoora. 2016

机译：具有微卫星不稳定性的大肠癌患者的突变谱； BRCA2和EGFR体细胞突变的频率高
6. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC and Subsequent Response to Osimertinib [O] . Maximilian J. Hochmair, Anna Buder, Sophia Schwab, -1

机译：基于液体活检的EGFR T790M突变介导的晚期EGFR突变阳性NSCLC患者对阿法替尼治疗的耐药性以及随后对奥西替尼的反应的鉴定
7. Ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd - generation EGFR-TKI-refractory NSCLC [O] . Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, 2021

机译：T790M与EGFR激活突变的比率预测Osimertinib在第1或第2代EGFR-TKI-REFCRATE NSCLC中的响应

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib

著录项

相似文献

相关主题

期刊订阅